ACAD Financial Facts
Collaborative revenues: 5.27MNet loss: -71.61M
See Full Income Statement
See Full Balance Sheet
ACADIA Pharmaceuticals (ACAD) Earnings
|
Expand Research on ACAD
| Next EPS Date | 5/1/24 | EPS Growth Rate | +122.2% |
|---|---|---|---|
| Average EPS % Beat Rate | +22.3% | Revenue Growth Rate | +76.1% |
| Average % Move 1-Wk after EPS | -5.1% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/1/24 | Q124 | N/A | $0.06 | N/A | N/A | $208.63M | N/A | N/A | N/A | ||
| 2/27/24 | Q423 | $0.28 | $0.29 | -$0.01 | $231M | $223.77M | N/A |  | | Details | |
| 11/2/23 | Q323 | -$0.40 | -$0.45 | +$0.05 | $211.7M | $192.2M | = | | | Details | |
| 8/2/23 | Q223 | $0.01 | -$0.10 | +$0.11 | $165.2M | $163.86M | = | | | Details | |
| 5/8/23 | Q123 | -$0.27 | -$0.21 | -$0.06 | $118.46M | $119.99M | = | | | Details | |
| 2/27/23 | Q422 | -$0.26 | -$0.25 | -$0.01 | $136.5M | $134.23M | = | | | Details | |
| 11/2/22 | Q322 | -$0.09 | -$0.19 | +$0.10 | $131.61M | $138.64M | = | | | Details | |
| 8/8/22 | Q222 | -$0.21 | -$0.25 | +$0.04 | $134.6M | $130.43M | = | | | Details |
